Table 1.
Patient Characteristics
| All Patients | PET Responders | PET Nonresponders | ||
|---|---|---|---|---|
| (n = 111) | (n = 70) | (n = 41) | p Value | |
| Age, years (range) | 64 (21-87) | 64 (36-87) | 65 (21-87) | 0.439 |
| Sex | 0.685 | |||
| Male | 69(62.2) | 42 (60) | 27 (65.9) | |
| Female | 42 (37.8) | 28 (40) | 14 (34.1) | |
| KPS (range) | 80 (70-90) | 90 (70-90) | 80 (70-90) | 0.157 |
| Tumor location | 0.886 | |||
| Upper | 27 (24.8) | 16 (22.9) | 11 (26.8) | |
| Mid | 43 (38.7) | 29 (41.4) | 14 (34.1) | |
| Lower | 32 (28.8) | 19 (27.1) | 13 (31.7) | |
| GE junction | 9 (8.1) | 6 (8.6) | 3 (7.3) | |
| Baseline staging | 0.254 | |||
| uT1-3N0 | 17 (15.3) | 13 (18.6) | 4 (9.8) | |
| uT2-3Nx | 6 (5.4) | 3 (4.3) | 3 (7.3) | |
| uT2-3N+ | 74 (66.7) | 50 (71.4) | 24 (58.5) | |
| uT4N0 | 2 (1.8) | 1 (1.4) | 1 (2.4) | |
| uT4N+ | 4 (3.6) | 1 (1.4) | 3 (7.3) | |
| Unknown | 8 (7.2) | 2 (2.9) | 6 (14.6) | |
| Baseline mSUV (range) | 13.5 (3.1-43.2) | 15.1 (3.9-35.5) | 11.6 (3.1-43.2) | 0.009 |
| Induction chemotherapy | 0.223 | |||
| Platinum/paclitaxel | 61 (55) | 41 (58.6) | 20 (48.8) | |
| Platinum/irinotecan | 43 (38.7) | 25 (35.7) | 19 (46.3) | |
| Irinotecan/docetaxel ± cisplatin | 6 (5.4) | 4 (5.7) | 2 (4.9) | |
| Capecitabine/oxaliplatin | 1 (0.9) | 1 (1.4) | 0 (0) |
Values are shown as n (%) unless otherwise noted. Bold values indicate significance.
PET, positron-emission tomography; GE, gastroesophageal; KPS, Karnofsky performance scale; mSUV, maximum standardized uptake value.